Previous 10 | Next 10 |
2024-07-23 19:32:16 ET Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could rea...
2024-07-23 11:27:10 ET More on American Conservative Values ETF Seeking Alpha’s Quant Rating on American Conservative Values ETF Dividend scorecard for American Conservative Values ETF Read the full article on Seeking Alpha For further details see: ...
2024-07-23 11:11:23 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly, Novo extend multi-day decline in rare selloff...
2024-07-23 10:30:00 ET Summary In Q2, data pointed to solid US economic activity and a sturdy labor market while inflation moved slowly toward the Fed’s 2% target. Global equity market results were mixed. Large caps furthered their advance as mega-cap technology platforms c...
2024-07-23 10:28:05 ET Summary Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 04:46:47 ET Summary I discuss my "Top 20 Stocks" list, focusing on high-quality companies with strong fundamentals and growth prospects. The list includes companies like S&P Global, Visa, Apple, and Waste Management, with brief explanations for each selection. I...
2024-07-21 21:02:13 ET More on health care stocks Elevance Health: Buy A Dividend Growth Machine Elevance extends losses as BofA cuts on Medicaid headwinds What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Merck: Among The Best Health Ca...
2024-07-21 07:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Bristol-Myers Squibb - Investors Are Too Long-Term Focused Bristol-Myers Squibb Is A Bargain Now AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Dividend Roundup: Gold...
2024-07-20 09:20:25 ET Summary VKTX's obesity therapy candidate, VK2735, demonstrates accelerated weight loss results compared to Wegovy/ Mounjaro and the next-gen candidates, including CagriSema/ Zepbound/ Retatrutide. This explains why the stock is trading at a notable premium c...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...